Angiotensin-converting enzyme inhibitors (ACE-is) and angiotensin II receptor blockers (ARBs) are key therapies in CKD management, shown to slow disease progression and reduce cardiovascular events by controlling blood pressure and mitigating albuminuria. Here, ACE is linked to chronic kidney disease.